Perivascular adipose tissue (PVAT) surrounds most blood vessels and secretes numerous active substances, including adiponectin, which produce a net anticontractile effect in healthy individuals. AMPK is a key mediator of cellular energy balance and may mediate the vascular effects of adiponectin. In this study, we investigated the role of AMPK within PVAT in mediating the anticontractile effect of PVAT.
Introduction
Perivascular adipose tissue (PVAT) surrounds almost all blood vessels and is increasingly recognized as an important regulator of vascular tone. As an active endocrine organ, the adipocytes and stromal cells within PVAT produce and secrete a range of adipokines, inflammatory cytokines and other factors, which can influence the tone of the underlying blood vessel Malinowski et al., 2008; Weston et al., 2013) . PVAT can release not only substances with vasodilator activity such as adipocyte-derived relaxing factor (Lohn et al., 2002; Verlohren et al., 2004; Galvez et al., 2006) , leptin (Vecchione et al., 2002) , adiponectin (Chen et al., 2003; Fesus et al., 2007) , angiotensin 1-7 (Ang 1-7) (Lee et al., 2009) , hydrogen peroxide , NO (Gil-Ortega et al., 2010) and hydrogen sulphide (H 2 S) (Fang et al., 2009 ) but also vasoconstrictor factors such as Ang II (Galvez-Prieto et al., 2008) and superoxide anions (Gao et al., 2006) . Consequently, a balance exists and much research effort has been channelled into discovering what causes the function of PVAT to change in disease states such as obesity and metabolic syndrome where PVAT has a deleterious effect on blood vessel activity.
PVAT is composed of brown adipocytes, white adipocytes or a mixture of both depending on the vascular bed (Gao, 2007; Cinti, 2011; Fitzgibbons et al., 2011) . In healthy humans and experimental animals, PVAT has a net anticontractile effect (Lohn et al., 2002; Greenstein et al., 2009) , but the precise mechanisms remain elusive. The anticontractile effect is probably due to the release of transmissible factors; a process that requires calcium but is not dependent on perivascular nerve activity . In rat mesenteric vessels, the anticontractile effect of PVAT is dependent on the activation of delayed rectifier potassium channels (K V ) in the vascular smooth muscle , while in rat aortic rings, Gao et al. found that a PVAT-derived transmissible factor induced relaxation by: (i) an endothelium-dependent effect via NO release and subsequent K Ca channel activation, and (ii) an endotheliumindependent mechanism involving H 2 O 2 and subsequent activation of soluble guanylyl cyclase (sGC; Gao et al., 2007) . More recent work has identified adiponectin as an abundant adipokine with anticontractile activity. In mouse mesenteric vessels and rat aorta, adiponectin was found to relax vascular smooth muscle cells (VSMCs) via K v channel opening and membrane hyperpolarisation (Fesus et al., 2007) . However, other studies using mouse mesenteric vessels found that adiponectin requires the presence of large conductance calcium-activated potassium channels (BK Ca ) in order to hyperpolarise VSMCs and exert an anticontractile effect (Lynch et al., 2013) . Interestingly, a recent study by Weston's group has shown that adiponectinmediated hyperpolarisation is inhibited by a selective inhibitor of AMP-activated protein kinase (AMPK) and that this effect of adiponectin is mimicked by the AMPK activator, A769662 . Activation of AMPK is proposed to trigger the opening of myocyte BK Ca channels and the release of NO, which accounts for the anticontractile effect of adiponectin. Indeed, in mice lacking the AMPKα2 catalytic subunit isoform, globular adiponectin failed to induce vascular relaxation (Meijer et al., 2013) suggesting that adiponectin requires AMPK to exert an anticontractile effect.
Although AMPK is often described as a cellular energy gauge and modulator of cellular metabolism (Hardie et al., 2003) , it also has important roles in maintaining vascular homeostasis (Ewart and Kennedy, 2011) . It is expressed throughout the vessel wall and can respond to changes in cellular energy state (Evans et al., 2005; Fleming et al., 2005) , hormonal changes (Nagata et al., 2004; Cheng et al., 2007) and drugs (Levine et al., 2007; Bilodeau-Goeseels et al., 2011; Ford et al., 2012) to regulate vascular tone. AMPK activation can induce vasodilatation via phosphorylation and activation of endothelial NOS (eNOS) at Ser 1177 (Morrow et al., 2003; Davis et al., 2006) and Ser 633 to increase NO production and vascular relaxation (Morrow et al., 2003; Davis et al., 2006) . AMPK can also induce endotheliumindependent relaxation by reducing the sensitivity of myosin light-chain kinase (MLCK) to intracellular calcium (Horman et al., 2008) . Collectively, these findings suggest that AMPK activation can not only induce vasodilatation but may also be involved in the vascular effects of PVAT. However, despite AMPKα1 being the dominant vascular isoform, nothing is known about its role in mediating the anticontractile effect of PVAT. The aim of this study was to investigate aortic PVAT function in a mouse with a global AMPKα1 isoform knockout (KO). Furthermore, investigated whether a lack of this AMPK isoform in the vascular wall affects the generation and vascular effects of adiponectin. 
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Methods
Animal model and artery preparation
Mice used in this study were housed at the University of Glasgow and maintained on 12 h cycles of light and dark and at ambient temperature. Wild type (Sv129-WT) mice were originally purchased from Harlan Laboratories (Oxon, UK). AMPKα 1 KO mice were kindly supplied by Benoit Viollet (Institut Cochin, Paris, France), the generation of which has been described previously (Jørgensen et al., 2004) . In all experiments, age-matched male and female WT and KO mice were used since pilot experiments showed no gender difference in vessel contractility and relaxation (data not shown (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
Histological analysis
Thoracic aortae with intact PVAT were fixed overnight in 10% acetic zinc formalin, dehydrated and embedded in paraffin. 
Small vessel wire myography
The thoracic and, in some experiments the abdominal aorta, was cut into 2 mm rings. Some rings were cleaned of PVAT, and others were left with the PVAT intact. In all cases, the endothelium on the luminal surface was removed by gently rubbing the interior of the vessel with a piece of fine wire and removal confirmed by lack of (<10%) vasodilator response to 10 À6 M acetylcholine. Artery rings were mounted on two stainless steel pins in a four channel wire myograph (Danish Myo Technology), set to an optimum tension of 9.8 mN (Weingartner et al., 2015) and allowed to equilibrate for at least 30 min before use. Vessels were bathed in Krebs buffer of the following composition: 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO 4 , 25 mM NaHCO 3 , 1.03 mM KH 2 PO 4 , 11 mM glucose and 2.5 mM CaCl 2 at 37°C and gassed continuously with 95% O 2 and 5% CO 2 . Reproducible responses were obtained to 40 mM KCl and 30 nM 9,11-dideoxy-9α,11α-methanoepoxy PGF 2α (U46619, Tocris) before commencing experiments. Cumulative concentration-response curves to the K + channel opener cromakalim (1 × 10 À9 to 1 × 10
Sigma-Aldrich, Poole, UK), added at 10 min intervals were constructed. Data are expressed as a percentage loss of U46619-induced tone.
To produce conditioned media (CM), thoracic aortic PVAT from WT and KO mice was carefully dissected, weighed and incubated in warmed Krebs solution at 37°C for 1 h. The conditioned medium was transferred to the recipient myograph chamber containing an aortic ring at baseline tension. The ring was then contracted and dose-response curves to cromakalim constructed as described previously. In some experiments, PVAT from KO mice was added to WT aortic rings and vice versa (termed a cross-over experiment).
To study the role of adiponectin in the anticontractile effect of PVAT, two separate experiments were performed. Firstly, 5 μg·mL À1 of an adiponectin blocking peptide against adiponectin receptor 1 (Adipo1 receptor; GeneTex, UK) was added to preconstricted aortic rings with and without PVAT. Secondly, globular adiponectin (1 μg·mL À1 diluted in 1% (w v À1 ) BSA; Enzo Life Sciences Ltd, UK) was added to arteries prior to contracting with U46619. In both cases, dose-response curves to cromakalim were then constructed in WT and KO aortic rings.
Effect of cromakalim on AMPK activity in cultured cells
Rat aortic smooth muscle cells from Wistar-Kyoto rats were provided by Dr Augusto Montezano (University of Glasgow) and maintained in DMEM supplemented with 10% (v v À1 )
FBS (Invitrogen, UK), 100 U·mL À1 pencillin and 100 μg·mL À1 streptomycin. At passage 4 to 5, the cells were washed with PBS and incubated in serum-free medium for 2 h. Cells were incubated with the AMPK-activating agent 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR; 10 À2 to 10 À3 M) or cromakalim (10 À8 to 10 À6 M) for 45 min, the medium was removed, lysis buffer was added [50 mM Tris pH 7.4, 50 mM NaF, 1 mM Na 4 P 2 O 7 , 1 mM EGTA, 1 mM EDTA, 1% (v v À1 ) Triton X-100, 1 mM DTT and 1% cocktail of protease inhibitors with 2 mM Na 3 VO 4 ] and the cells were collected by scraping. Lysates were placed BJP T A M Almabrouk et al.
on ice for 30 min, centrifuged at 6.2× g for 10 min, and supernatants were collected and used for immunoblotting. 
Protein expression/immunoblotting
Array and adiponectin ELISA
Adipokine expression profiling was performed using an adipokine proteome profiler, (R&D systems, UK) following the protocol provided by the manufacturer. Briefly, 1 mL of pooled samples of homogenized PVAT or conditioned medium from WT and KO mice were added to the array membranes and incubated at 4°C overnight. After being washed, membranes were incubated with 2 mL of horseradish peroxidase-conjugated streptavidin at room temperature for 30 min and the presence of adipokines were detected by chemiluminescence. The resultant film images were scanned with a densitometer and converted to densitometric units using Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA). Data were normalised against an internal control as recommended by the manufacturer. To study adiponectin release by PVAT, a mouse adiponectin/Acrp30 Quantikine ELISA Kit (MRP300, R&D systems, Minneapolis, MN) was used. Samples of homogenized PVAT and CM from WT and KO mice were prepared and protein concentration determined. Adiponectin was detected as a colourimetric reaction measuring absorbance of the ELISA plate at 450 nm with wavelength correction using a FLUOstar OPTIMA microplate reader (BMG Labtech, Germany). The mean absorbance from each sample was measured in duplicate and the adiponectin concentration was determined by comparison with the standard curve.
Statistical analysis
All results are expressed as mean ± SEM. The n number stated in all cases represents the number of mice from which tissue was obtained. Data were analysed with GraphPad Prism 5.0 software. Myography data were analysed using two-way ANOVA. When comparing three or more data groups, twoway ANOVA followed by Bonferroni post hoc tests were used. When comparing two or more data groups, a Newman-Keuls post hoc test was used. In all cases, a P value of less than 0.05 was considered statistically significant. The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Results
PVAT morphology and AMPK expression
In haematoxylin and eosin stained sections, there were no gross differences in PVAT or other fat depots between WT and AMPKα 1 KO mice (Figure 1) . In both strains, thoracic PVAT had the appearance of BAT with round nuclei, and small, multilocular lipid droplets, whereas mesenteric PVAT was very similar to WAT, with large single lipid vacuoles and marginal nuclei. Abdominal PVAT showed features of both BAT and WAT. Immunohistochemical staining for the BAT marker UCP1 was similar in WT and KO aortic PVAT with very low staining in mesenteric fat and some staining present in abdominal aortic PVAT (Supplementary Figures S1  and S2 ).
AMPKα and phospho-AMPKα (pAMPKα) were detected immunohistochemically in thoracic PVAT, and there was a marked reduction in both total and phospho-AMPKα Thr 172 in KO mice (data not shown). Western blotting was used to quantify AMPK levels in homogenized PVAT. As expected, there was a marked reduction in total levels of AMPKα, phospho-AMPKα Thr 172 and phospho-ACC Ser 79 (pACC).
When expressed relative to total AMPKα, there was a modest reduction in the level of phosphorylated AMPKα in KO mice in comparison with WT ( Figure 2 ). There was no substantial difference in AMPKα2 immunoreactivity between genotypes.
Anticontractile effect of PVATand importance of AMPK
The presence or absence of the vascular endothelium did not affect the contractile response to U46619 in WT or KO aortae (data not shown). In aortic rings without PVAT there was no significant difference in contraction between WT and KO mice ( Figure 3A) . In rings containing PVAT, contractions to U46619 were significantly reduced in the WT but not the KO mice ( Figure 3A) , indicating an anticontractile effect of the PVAT which was lost when the PVAT was deficient in AMPKα1.
The presence of PVAT significantly increased the relaxation to cromakalim in thoracic aortic rings from WT mice, but this effect was completely absent in those from AMPKα1 KO mice ( Figure 3B, C) . To check that the effect of PVAT was not specific to the thoracic aorta, the experiment was repeated in abdominal aorta and similar results were found: in WT vessels with intact PVAT, maximum relaxation (E max ) to cromakalim was significantly higher, 53.3 ± 5.2%, with PVAT than without PVAT, 24.5 ± 5.7% (n = 6) while in KO mice PVAT had no effect on E max to cromakalim (22.8 ± 5.8% vs. 17.4 ± 4.1%, n = 6).
In WT mice, PVAT, which had been dissected free of the artery and added back into the organ bath, was able to augment relaxation to cromakalim equally as well as when the PVAT was in contact with the artery (E max 54.5 ± 8.3% vs. 49.9 ± 6.7%; n = 5), suggesting that the PVAT releases a transmissible factor, which is responsible for increased relaxation. In contrast, addition of PVAT from KO mice to an aortic ring 
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from WT mice did not augment relaxation to cromakalim ( Figure 4A , B) whereas adding WT PVAT to a KO aortic ring did augment relaxation. Furthermore, addition of CM produced by WT PVAT was able to augment cromakalim-induced relaxation in WT aortic rings while CM produced by KO PVAT was unable to augment relaxation in these rings ( Figure 4C,  D) . WT CM also significantly attenuated contraction to U46619 in WT rings without PVAT (1.19 ± 0.1 g vs. 0.86 ± 0.1 g with addition of CM; n = 12). In contrast, KO CM showed a non-significant trend towards increased contraction (2.33 ± 1.3 g vs. 2.80 ± 1.4 g with addition of CM; n = 12). Transfer of WT PVAT into KO vessels without PVAT and CM experiments indicates that the deficiency in the KO mouse is likely to be at least partly related to differences in the release of adipokines by the PVAT.
Cromakalim does not activate AMPK in vascular smooth muscle cells
To rule out the possibility that the vasodilatation to cromakalim is altered in KO mice because cromakalim activates AMPK, cultured rat VSMCs were treated with a range of concentrations of cromakalim and the AMPK activator AICAR as a positive control. Cromakalim did not increase the phosphorylation of AMPK in the vascular smooth muscle and had no effect on the phosphorylation of the downstream substrate ACC. AICAR caused an increase in AMPK activity (Supplementary Figure S3) at a concentration of 10 À3 M.
Adipocytokine profile and effect of AMPK KO
Adipocytokine profiling of PVAT-derived CM showed a striking reduction in the amount of adiponectin released by PVAT from AMPKα1 KO mice (n = 2; data not shown). Further quantification of this difference by ELISA in n = 5 samples of conditioned medium from KO and WT mice revealed a significant reduction in the quantity of adiponectin released by KO PVAT ( Figure 5 ).
Effect of adiponectin on vessel function
Addition of globular adiponectin to WT aortic rings without PVAT significantly increased relaxation to cromakalim ( Figure 6A ). Interestingly, globular adiponectin enhanced the relaxation to cromakalim in KO vessels both with and without PVAT ( Figure 6B, C) . Blocking adiponectin receptors in WT aortic rings with intact PVAT significantly attenuated relaxation to cromakalim ( Figure 7A ), while in KO arteries with intact PVAT, the blocking peptide had no effect ( Figure 7B ). Taken together, these results suggest that KO PVAT releases less adiponectin but that the medial smooth Figure 2 Western blots showing the expression of AMPKα isoforms and expression of the downstream kinase ACC in PVAT from WT (right lanes) and KO mice (left lanes). KO mouse PVAT showed a reduction in expression of AMPKα1 and total AMPKα with no change in AMPKα2. KO PVAT also had significantly reduced phosphoAMPK and ACC. *P < 0.05, KO compared to WT PVAT; n = 5.
muscle cells are still able to respond to exogenously added adiponectin.
Discussion
The main findings of this study are that the anticontractile effect of aortic PVAT is lost in mice that lack AMPKα1, and this is due to the reduced generation of a transmissible factor, probably adiponectin, by the PVAT. The results also demonstrate that the lack of an anticontractile effect in the KO mouse is not due to alterations in PVAT morphology or the ratio of BAT to WAT or to the absence of AMPK expression in the medial smooth muscle cells of the aorta. Since incubation with globular adiponectin augmented relaxation to cromakalim in KO arteries without PVAT, it is also unlikely to be due to a reduced sensitivity of the medial VSMCs to adiponectin. In summary, AMPKα1 plays a critical role in maintaining the anticontractile actions of PVAT; an effect independent of the endothelium but likely to be mediated through altered adiponectin secretion. Morphological studies revealed no difference in PVAT from WT and KO mice. The thoracic aorta was similar in appearance to depots of BAT from the subscapsular region while abdominal aorta showed a mixture of WAT and BAT. This is in agreement with previous studies using Sv129 mice (Frontini and Cinti, 2010; Cinti, 2011) and also from other mouse strains (Cannon and Nedergaard, 2004; Fitzgibbons et al., 2011; Padilla et al., 2013) . It has been speculated that differences in PVAT phenotype could contribute to disease susceptibility of certain regions of the arterial tree (Jeong et al., 2007; Greif et al., 2009) , possibly through the release of pro-inflammatory cytokines (Zhao et al., 2003; Chatterjee et al., 2009; Payne et al., 2010) . Certainly, in animal models of obesity, there is evidence for a detrimental effect of PVAT on vascular function in aortic (Ma et al., 2010) and mesenteric arteries (Marchesi et al., 2009; Ketonen et al., 2010) , and in animals fed a high fat diet, there was reduced phosphorylation of AMPK in thoracic aortic PVAT, an increased adipocyte size and increased intimal thickness (Ma et al., 2010) . Taken together, these studies suggest that AMPK in the PVAT is likely to be protective and this agrees with the data presented here showing that the anticontractile effect of thoracic (and abdominal) PVAT is lost in mice lacking AMPKα1. We also demonstrated that in the KO mouse, there was reduced phosphorylated and total AMPK in PVAT as well as reduced phosphorylation of the downstream kinase ACC. There was also no obvious compensatory up-regulation in AMPKα2 isoforms. The dramatic effect of AMPK α1 KO on PVAT function is in agreement with other studies showing that in adipose Figure 3 (A) U46619-induced contraction was not significantly different in WT and KO thoracic aorta rings in the absence of PVAT. In vessels with attached PVAT, there was a significant reduction in contraction in WT but not KO aortic rings. (n = 7; *P < 0.05). (B) The presence of PVAT significantly augmented the relaxation to chromakalim in WT aortic rings [n = 7; *P < 0.05 vs. PVAT(À)]. (C) In aortic rings from AMPKα1 KO mice, the presence of PVAT had no effect on relaxation to cromakalim (n = 7).
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tissue the catalytic α1 subunit is the major isoform expressed and is also responsible for the major part of AMPK's activity (Lihn et al., 2004; Daval et al., 2005) .
The lack of AMPKα1 caused the PVAT to lose its anticontractile effect and its presence no longer augmented relaxation to cromakalim. To rule out any differences being due to cromakalim acting through AMPK, we added cromakalim to cultured VSMCs and found it had no effect on AMPK expression or phosphorylation. Many other studies have found an anticontractile effect of PVAT in a variety of vascular beds (Gao et al., 2005b; Greenstein et al., 2009) and in vessels contracted with several different vasoconstrictor agents including phenylephrine, 5-HT, Ang II and U46619 (Lohn et al., 2002; Verlohren et al., 2004; Gao et al., 2005a) . The mechanism has been proposed as release of transferable relaxation factor(s), termed adventitia-derived relaxation factor (ADRF). The nature of ADRF is largely unknown. However, it has been shown to act in part via activation of K + channels and tyrosine kinase and independently of NO and sympathetic nerve stimulation (Lohn et al., 2002) . Our data agree with this in that transfer of CM from WT mice augmented relaxation of aortic rings with PVAT. In addition, it was not necessary for the PVAT to be in contact with the vessel to exert an anticontractile effect. In our protocol, we added the CM prior to contraction of the vessel ring with U46619 and found that WT but not KO CM attenuated aortic contraction. This strongly suggests a transmissible factor is responsible for the attenuation of the contraction and increased relaxation induced by aortic PVAT, and in the KO mice, this factor is reduced or absent. The deficiency in the KO mouse is unlikely to be due to a lack of AMPK in the medial smooth muscle cells since in crossover studies, WT PVAT was able to augment the relaxation response to cromakalim in KO vessels. However, it is worth noting that relaxations to cromakalim tended to be
Figure 4
In crossover experiments using aortic rings without PVAT, the addition of WT PVAT enhanced cromakalim-induced relaxation in KO aortic rings (A). However, the addition of KO PVAT to WT aortic rings (B) did not significantly alter the relaxation to cromakalim [n = 6; *P < 0.05 vs. PVAT(À)]. CM from WT aortic PVAT significantly enhanced relaxation to cromakalim (C) while KO CM had no effect on relaxation to cromakalim (D) [n = 6; *P < 0.05 vs. PVAT(À)].
Figure 5
Adiponectin concentration of CM from WT and KO mice determined using an ELISA kit. WT PVAT released significantly more adiponectin than KO PVAT (*P˂0.05; n = 5).
lower in KO rings without PVAT and while exogenously added WT PVAT or WT CM significantly augmented relaxation to cromakalim in KO aortic rings, it still did not reach levels seen in WT vessels with intact PVAT. This suggests there may be some deficit in the function of the VSMCs in the KO mice and future experiments should use an adipocyte-specific AMPK KO to address this. The release of vasorelaxing factors (ADRF) has been reported to be dependent on calcium and is regulated by intracellular signalling pathways involving tyrosine kinase and
Figure 7
In aortic rings with intact PVAT, addition of 5 μg·mL À1 of the Adipo1 receptor blocking peptide significantly attenuated the relaxation to cromakalim in WT mice (A) but had no effect in rings from KO mice (B). [n = 6, *P < 0.05 vs PVAT(+)]. (Fasshauer et al., 2002; Maeda et al., 2002; Lihn et al., 2003) , indicating that the activity of AMPK in the PVAT could regulate adiponectin expression (Lihn et al., 2004) . Similarly, the PPARγ agonist troglitazone, which also activates AMPK, has a positive effect on adiponectin expression in mature adipocytes (Phillips et al., 2003) . However, other studies using cultured 3T3-L1 adipocytes found that prolonged exposure to AMPK activating agents actually causes a significant reduction in the adiponectin protein content of the adipocytes (Huypens et al., 2005) . To clarify how AMPKα1 KO affects the secretion of adipocytokines by aortic PVAT, we performed an array and the most striking difference was a reduction in adiponectin in KO PVAT and CM. Quantitative studies using ELISA further confirmed a significant reduction in adiponectin in KO CM. Since adiponectin is a vasodilator (Fesus et al., 2007) , it could account for the lack of an anticontractile effect in KO PVAT. Indeed, in WT mice, the anticontractile effect of PVAT was abolished using a adiponectin receptor blocking peptide, an effect demonstrated previously in human gluteal arteries (Fesus et al., 2007) and mouse mesenteric arteries (Lynch et al., 2013) . We also demonstrated that the relaxation response to cromakalim was increased in aortic rings of both KO and WT without PVAT by pretreating the rings with globular adiponectin. Since all rings were denuded of endothelium, this suggests adiponectin has direct access to VSMCs . The adiponectin-enhanced vascular relaxation was also observed in KO vessels with intact PVAT, indicating that there was no perfusion barrier between the PVAT and vascular smooth muscle layer. Additionally, vascular relaxation was seen in both WT and AMPKα1 KO vessels suggesting that adiponectin can act directly on VSMCs and that the AMPKα1 isoform is not involved.
Only one vasodilator was used in the current study; the K ATP channel activator cromakalim. K ATP channels in VSMCs may be involved in mediating the anticontractile effects of PVAT since a previous study showed glibenclamide inhibits these effects (Lohn et al., 2002) . K ATP channels appear to regulate basal tone in a number of vascular beds, such as the coronary circulation (Samaha et al., 1992) and mesenteric vessels (Nelson and Quayle, 1995) , and inhibition of this channel by glibenclamide has been found to attenuate the autoregulation of coronary and cerebral vessels (Narishige et al., 1993; Hong et al., 1994) . In our study, since PVAT enhanced the relaxation induced by cromakalim, adiponectin released by the PVAT may act in part through modulating K ATP channels. However, the role and the mechanism of activation need to be investigated further.
In conclusion, we have shown that PVAT has a profound anticontractile effect on mouse aortic rings. This effect may be due to the release of adiponectin by the PVAT and this release is regulated by the activity of AMPKα1. In mouse aortic rings, adiponectin augments the relaxation to cromakalim in an endothelium-independent manner, although other effects of adiponectin on the endothelium cannot be ruled out. Indeed, although aortic rings in this study were mechanically denuded of the endothelium, endothelial cells in vessels within the vasa vasorum will remain and adiponectin may have effects here. Clinically, there is evidence that PVAT becomes dysfunctional in obese humans and plasma adiponectin levels are reduced (Aghamohammadzadeh et al., 2015) . Alterations in AMPK activity in the PVAT may be behind this effect. Figure S1 Brown adipose tissue marker (UCP1) present in different depots of adipose tissue from both wild type and AMPKα 1 knockout mice. Representative histological sections of brown adipose tissue (BAT) (A&B), white adipose tissue (WAT)(C&D), thoracic PVAT (E&F), abdominal PVAT (G&H) and mesenteric PVAT (I&J) stained with anti UCP1 and counterstained with haematoxylin. Positive immunoreactivity for UCP1 is indicated by brown colour. (AO = aorta, MA = mesenteric artery, scale bar 20 μm, magnification ×20). Figure S2 Brown adipose tissue marker (UCP1) expression in different PVAT depots. UCP1 expression was divided by GAPDH to adjust for protein loading. Western blots were performed in BAT (brown adipose tissue); WAT (white adipose tissue); TA (thoracic artery PVAT); AA (abdominal aorta PVAT); MES (mesenteric artery PVAT) from WT and KO homogenates. Blot shown are representative n = 3 for all groups. Figure S3 AMPK expression and activity in cultured rat aortic vascular smooth muscle cells (VSMCs). VSMCs samples were treated with AICAR and cromakalim, lysed and immunoblotting was performed. Graphs are expressed as the foldchange of the phosphorylated form of each enzyme divided by the total AMPKα (B) or total ACC (C) to measure the activation of the enzyme. Blots shown are representative; n = 3 for all groups.
